| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/06/2006 | US20060073166 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR |
| 04/06/2006 | US20060073164 Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| 04/06/2006 | US20060073162 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| 04/06/2006 | US20060073155 Methods and compositions for diseases associated with amyloidosis |
| 04/06/2006 | US20060073150 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers |
| 04/06/2006 | US20060073147 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| 04/06/2006 | US20060073146 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 04/06/2006 | US20060073140 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 04/06/2006 | US20060073138 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 04/06/2006 | US20060073137 Humanised antibodies |
| 04/06/2006 | US20060073136 Humanised antibodies |
| 04/06/2006 | US20060073134 Determining in a pancreas sample the level of expression of a marker protein; islet cell regeneration factor; lithostathine 1 alpha, leukocyte elastase inhibitor, lipocalin-2; indicates diabetes |
| 04/06/2006 | US20060073132 Administering fragments of alpha-1 proteinase inhibitor (API) or chimeric proteins of API and insulin-like growth factor for use in stimulating wound healing |
| 04/06/2006 | US20060073131 Coenzyme Q compositions persisting in blood |
| 04/06/2006 | US20060073130 reducing a symptom of psoriasis by administering a composition comprising Bacillus coagulans bacteria in an amount effective to reduce serum TNF- alpha levels; skin disorders |
| 04/06/2006 | US20060073128 Means and methods for the modulation of arteriogenesis |
| 04/06/2006 | US20060073115 Autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis, inflamamatory disorders or infection by microorganisms |
| 04/06/2006 | US20060073114 Compounds and methods to inhibit or augment an inflammatory response |
| 04/06/2006 | US20060073105 Novel dry powder inhalation system for transpulmonary administration |
| 04/06/2006 | US20060073098 Irrigating solution for neurosurgical procedures |
| 04/06/2006 | DE102004054545A1 Änderung des Beladungszustandes von MHC-Molekülen Changing the load state of MHC molecules |
| 04/06/2006 | DE102004047262A1 Pharmazeutisches Mittel umfassend Blutprodukte und deren Verwendung als Injektions- oder Infusionsmittel zur Prophylaxe und Behandlung von Defekten des Immunsystems beim Menschen A pharmaceutical composition comprising blood products and their use as injection or infusion agent for the prophylaxis and treatment of defects of the immune system in humans |
| 04/06/2006 | DE102004045705A1 Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen Uses of the carbamoyl phosphate synthetase 1 (CPS) as humoral biomarkers for the diagnosis of tumor diseases and chronic inflammatory bowel disease |
| 04/06/2006 | CA2582958A1 Rehydration compositions comprising epidermal growth factor |
| 04/06/2006 | CA2582940A1 Myostatin isoform |
| 04/06/2006 | CA2582226A1 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 04/06/2006 | CA2582224A1 Compositions and methods for modulating tissue regeneration and chemotactic responses |
| 04/06/2006 | CA2582073A1 Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
| 04/06/2006 | CA2582041A1 Recombinant human t2 rnase and uses thereof |
| 04/06/2006 | CA2581980A1 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 04/06/2006 | CA2581966A1 Group a streptococcus crge protein |
| 04/06/2006 | CA2581927A1 Treatment or prevention of unscheduled bleeding in women on progestogen containing medication |
| 04/06/2006 | CA2581883A1 Novel antimicrobial agents |
| 04/06/2006 | CA2581787A1 Use of tgf-b antagonists to limit nephrotoxicity of immunosuppressive agents |
| 04/06/2006 | CA2581769A1 Methods of using chimeric coiled-coil molecule |
| 04/06/2006 | CA2581680A1 Kallikrein inhibitors and uses thereof |
| 04/06/2006 | CA2581527A1 Antibacterial amide macrocycles iv |
| 04/06/2006 | CA2581331A1 Listeria-based and llo-based vaccines |
| 04/06/2006 | CA2580957A1 Methods for the treatment and prevention of diseases of biological conduits |
| 04/06/2006 | CA2580780A1 Frizzled proteins and detection and treatment of cancer |
| 04/06/2006 | CA2577821A1 Combination therapy for the treatment of obesity |
| 04/05/2006 | EP1642981A1 RECOMBINANT GENE MEDICINE OF ADENOVIRUS VECTOR AND GENE p53 FOR TREATING PROLIFERATIVE DISEASES |
| 04/05/2006 | EP1642979A1 Fucosyltransferase gene |
| 04/05/2006 | EP1642975A2 Chemokine receptors 88-2B (CKR-3) and their antibodies |
| 04/05/2006 | EP1642974A1 Recombinant soluble Fc receptors |
| 04/05/2006 | EP1642973A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642972A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642909A2 Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
| 04/05/2006 | EP1642903A1 Peptide having apoptosis-inhibiting activity |
| 04/05/2006 | EP1642591A1 MEDICINAL COMPOSITION CONTAINING NF-kAPPA B DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME |
| 04/05/2006 | EP1642588A2 Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease |
| 04/05/2006 | EP1642586A1 Cell-containing preparations |
| 04/05/2006 | EP1642584A1 External preparation for improving coital function |
| 04/05/2006 | EP1642138A1 Secreted polypeptide species reduced in cardiovascular disorders |
| 04/05/2006 | EP1642135A1 Method for diagnosing inflammatory bowel disease |
| 04/05/2006 | EP1641927A2 Induced activation in dendritic cells |
| 04/05/2006 | EP1641926A2 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 04/05/2006 | EP1641919A2 Applications of a new class of enzymes: sulfiredoxines |
| 04/05/2006 | EP1641824A1 Relaxin superfamily peptide analogues |
| 04/05/2006 | EP1641823A2 Glp-1 analog fusion plroteins |
| 04/05/2006 | EP1641822A2 Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| 04/05/2006 | EP1641820A1 Rasgap derived peptide for selectively killing cancer cells |
| 04/05/2006 | EP1641818A1 Polypeptides having binding affinity for her2 |
| 04/05/2006 | EP1641815A2 Uranium-chelating peptides and uses thereof |
| 04/05/2006 | EP1641813A2 Methods for obtaining molecules with reduced immunogenicity |
| 04/05/2006 | EP1641488A1 Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| 04/05/2006 | EP1641487A1 Liquid composition of factor vii polypeptides |
| 04/05/2006 | EP1641486A1 Stable, aqueous solution of human erythropoietin, not containing serum albumin |
| 04/05/2006 | EP1641485A1 Inhibition of sars coronavirus infection with clinically approved antiviral drugs |
| 04/05/2006 | EP1641484A2 Treatment of inflammatory respiratory diseases |
| 04/05/2006 | EP1641483A2 Fusion proteins |
| 04/05/2006 | EP1641482A1 Method of treatment of systemic injury secondary to burns |
| 04/05/2006 | EP1641481A2 Formation of novel erythropoietin conjugates using transglutaminase |
| 04/05/2006 | EP1641480A1 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
| 04/05/2006 | EP1641479A2 Inhibition of stress-induced ligand-dependent egfr activation |
| 04/05/2006 | EP1641437A1 The solid dispersion of tacrolimus |
| 04/05/2006 | EP1641436A1 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| 04/05/2006 | EP1641434A1 Pharmaceutical formulations for intranasal administration of protein comprising chitosan or a derivative thereof |
| 04/05/2006 | EP1641431A2 Uses of il-12 in hematopoiesis |
| 04/05/2006 | EP1641424A2 Programmed immune responses using a vaccination node |
| 04/05/2006 | EP1641421A2 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| 04/05/2006 | EP1556490A4 Novel nucleic acids and polypeptides |
| 04/05/2006 | EP1509546A4 Collagen and method for producing same |
| 04/05/2006 | EP1309701B1 Myrosinase from brevicoryne brassicae |
| 04/05/2006 | EP1289504B1 Neurotoxin implant |
| 04/05/2006 | EP1210104B1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| 04/05/2006 | EP1205186B1 Adrenomedullin for ameliorating urination disorders |
| 04/05/2006 | EP1198235A4 Method of promoting bone growth with hyaluronic acid and growth factors |
| 04/05/2006 | EP1147413B1 Growth differentiation factor inhibitors and uses therefor |
| 04/05/2006 | EP1140192B1 Use of the cyclooxygenase-2 inhibitor celecoxib and capecitabine for combination therapy in neoplasia |
| 04/05/2006 | EP1115417B1 Use of daptomycin |
| 04/05/2006 | EP1102785A4 COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
| 04/05/2006 | EP1094824B1 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 04/05/2006 | EP1085901B1 Transdermal use of secretin for the treatment of autism |
| 04/05/2006 | EP1049718B1 Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin |
| 04/05/2006 | EP0991660B8 DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS |
| 04/05/2006 | EP0963207B1 IL12 for the gene therapy of tumours |
| 04/05/2006 | EP0946188B1 Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
| 04/05/2006 | EP0941364B1 Process aimed at evidencing the state of a malignant cell and process for treatment |
| 04/05/2006 | EP0871673B1 Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety |